Log in

Oramed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ORMP)

$3.04
-0.01 (-0.33 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$2.99
Now: $3.04
$3.10
50-Day Range
$2.86
MA: $3.13
$3.32
52-Week Range
$2.78
Now: $3.04
$4.69
Volume45,171 shs
Average Volume43,908 shs
Market Capitalization$52.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
CUSIPN/A
Phone844-967-2633

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.45 million
Book Value$1.79 per share

Profitability

Net Income$-12,720,000.00
Net Margins-568.43%

Miscellaneous

EmployeesN/A
Market Cap$52.84 million
Next Earnings Date11/27/2019 (Estimated)
OptionableOptionable

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.


Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 27th 2019. View Earnings Estimates for Oramed Pharmaceuticals.

What price target have analysts set for ORMP?

2 brokers have issued 12 month price targets for Oramed Pharmaceuticals' shares. Their predictions range from $7.00 to $20.00. On average, they expect Oramed Pharmaceuticals' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 344.1% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

What is the consensus analysts' recommendation for Oramed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

Has Oramed Pharmaceuticals been receiving favorable news coverage?

Headlines about ORMP stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Oramed Pharmaceuticals.

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 67,000 shares, an increase of 10.6% from the August 30th total of 60,600 shares. Based on an average daily volume of 49,700 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.5% of the shares of the stock are short sold. View Oramed Pharmaceuticals' Current Options Chain.

Who are some of Oramed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oramed Pharmaceuticals own?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:
  • Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
  • Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $3.04.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $52.84 million and generates $2.45 million in revenue each year. The biotechnology company earns $-12,720,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 142 WEST 57TH STREET, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]


MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  414
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel